Systemic Immune-Inflammation Index in Endocrine and Metabolic Disorders

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (20 May 2024) | Viewed by 1128

Special Issue Editor


E-Mail Website
Guest Editor
First Pediatric Clinic, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania
Interests: obesity; metabolic diseases; thyroid adrenal and bone diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Endocrine and metabolic diseases are a global health concern, primarily due to the escalating prevalence of childhood obesity, which often leads to long-term health outcomes. In the dynamic landscape of medical research, understanding the intricate relationship between endocrine/metabolic disorders, the immune system, and inflammation is crucial. Apart from conventional biomarkers, hematologic indices are gaining attention in numerous chronic diseases as a means to quantify inflammation. The systemic immune-inflammation index incorporates key hematological parameters, providing a holistic understanding of the body's immune and inflammatory status. This Special Issue provides a unique platform for authors to explore the relationship between the systemic immune-inflammation index and pediatric endocrine and metabolic diseases.

We invite researchers, healthcare professionals, and experts in the field to submit their original research, reviews, case studies, and perspectives for consideration. Authors are encouraged to explore topics such as immune modulation, immunometabolism, and therapeutic interventions related to endocrine and metabolic disorders. Your work may have a profound impact on the development of strategies to improve the early recognition and thus proper management of these diseases.

Join us in this vital dialogue by submitting your articles, and be part of the solution addressing the challenges posed by disorders such as childhood diabetes, obesity, and thyroid dysfunction. Together, we can pave the way towards a healthier future for younger generations.

Prof. Dr. Otilia Marginean
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammation biomarkers
  • immunometabolism, chronic inflammation
  • metabolic dysfunction
  • immune–metabolic crosstalk
  • endocrine disorders

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 1660 KiB  
Article
Multidimensional Assessment of Sarcopenia and Sarcopenic Obesity in Geriatric Patients: Creatinine/Cystatin C Ratio Performs Better than Sarcopenia Index
by Mohamad Khalil, Agostino Di Ciaula, Nour Jaber, Roberta Grandolfo, Flavia Fiermonte and Piero Portincasa
Metabolites 2024, 14(6), 306; https://doi.org/10.3390/metabo14060306 - 27 May 2024
Cited by 1 | Viewed by 677
Abstract
The serum creatinine/cystatin C ratio (CCR) and the sarcopenia index (SI) are novel indicators for sarcopenia, but their accuracy may depend on various confounders. To assess CCR and SI diagnostic accuracy, we studied the clinical and biophysical parameters associated with sarcopenia or sarcopenic [...] Read more.
The serum creatinine/cystatin C ratio (CCR) and the sarcopenia index (SI) are novel indicators for sarcopenia, but their accuracy may depend on various confounders. To assess CCR and SI diagnostic accuracy, we studied the clinical and biophysical parameters associated with sarcopenia or sarcopenic obesity. A total of 79 elderly patients (65–99 yrs, 33 females) underwent clinical, anthropometric, body composition, geriatric performance, and blood chemistry evaluation. The CCR and SI accuracy were assessed to identify sarcopenia. Sarcopenia was confirmed in 40.5%, and sarcopenic obesity in 8.9% of the subjects. Sarcopenic patients showed an increased Charlson comorbidity index, cardiovascular disease (CVD) rates and frailty, and decreased physical performance than non-sarcopenic subjects. Patients with sarcopenic obesity had increased body fat and inflammatory markers compared to obese subjects without sarcopenia. Sarcopenia was associated with a decreased CCR and SI. However, when the logistic regression models were adjusted for possible confounders (i.e., age, gender, Charlson comorbidity index, presence of CVD, and frailty score), a significant OR was confirmed for the CCR (OR 0.021, 95% CI 0.00055–0.83) but not for the SI. The AUC for the CCR for sarcopenia discrimination was 0.72. A higher performance was observed in patients without chronic kidney diseases (CKD, AUC 0.83). CCR, more than the SI, is a useful, non-invasive, and cost-effective tool to predict sarcopenia, irrespective of the potential confounders, particularly in subjects without CKD. Full article
Show Figures

Figure 1

Back to TopTop